XBIT — XBiotech Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1626878 ·
Last close
$2.15
Market Cap
$65.55M
52W High
$3.44
52W Low
$2.09
ADV30
44,636
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -6,146,000 -6,728,000 133,651,000 109,528,000 5,190,000
Mar 2026 0 — -6,274,000 -5,505,000 139,836,000 115,459,000 4,819,000
Dec 2025 0 — -29,755,000 -26,892,000 150,082,000 125,551,000 9,732,000
Sep 2025 0 — -6,047,000 -6,008,000 172,424,000 147,367,000 5,344,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-42,169,000
Investing CF
$-186,000
Financing CF
$0
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.80
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-141,882,000
Inventory
—
Receivables
$302,000
ST Investments
—
EBIT TTM
$-39,906,000
Pretax Income TTM
$-39,906,000
Interest Exp TTM
$0
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -55,685,000 -45,540,000 150,082,000 9,732,000 140,350,000 -39,920,000
Dec 2024 0 -42,471,000 -38,531,000 199,093,000 16,825,000 182,268,000 -30,963,000
Dec 2023 0 -37,510,000 -24,557,000 226,615,000 7,769,000 218,846,000 -18,725,000
Dec 2022 4,010,000 -34,490,000 -32,900,000 246,103,000 5,701,000 240,402,000 -14,824,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.13

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.15 · call volume: 1 · put volume: 3
Expected Move to 2026-10-16: ±$0.45 (20.93%) — implied range $1.70 – $2.60 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PLRX PLIANT THERAPEUTICS, INC. $66.88M $1.08 —
ATHE ALTERITY THERAPEUTICS LTD $63.73M $3.50 —
CNTB Connect Biopharma Holdings Ltd $68.01M $1.08 —
HYFT MindWalk Holdings Corp. $62.96M $1.34 —
RNTX Rein Therapeutics, Inc. $62.20M $0.72 —

News headlines (Yahoo Finance, 1h cache)

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
2026-06-15 13:00 · Yahoo
3 Promising Penny Stocks With Market Caps Over $30M
2025-12-19 18:05 · Yahoo
November 2025's Promising Penny Stocks To Watch
2025-11-12 18:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.